Aurum Wealth Management Group »

Fs Global Cr Opportunitie Fda shares owned by Aurum Wealth Management Group

Quarter-by-quarter ownership of Fs Global Cr Opportunitie Fda (FSCO) shares owned by Aurum Wealth Management Group from 13F filings

Historical chart of Aurum Wealth Management Group investment in Fs Global Cr Opportunitie Fda

Tip: Access up to 7 years of quarterly data

All positions including Fs Global Cr Opportunitie Fda held by Aurum Wealth Management Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fs Global Cr Opportunitie Fda by Aurum Wealth Management Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $328k 58k 5.67
2023-09-30 $313k 58k 5.42
2023-06-30 $274k 58k 4.75
2023-03-31 $179k 40k 4.44
2022-12-31 $108k 23k 4.71

More positions owned by Aurum Wealth Management Group

Ishares Tr Core S&p500 Etf (IVV)
Schwab Strategic Tr Us Lrg Cap Etf (SCHX)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Schwab Strategic Tr Us Sml Cap Etf (SCHA)
Vanguard Index Fds Small Cp Etf (VB)
Ishares Tr Core Msci Eafe (IEFA)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Ishares Tr Core S&p Scp Etf (IJR)
Vaneck Etf Trust Cef Muni Income (XMPT)
Apple (AAPL)
United Parcel Service CL B (UPS)
Microsoft Corporation (MSFT)
Ishares Core Msci Emkt (IEMG)
Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)

View all positions for Aurum Wealth Management Group

Top funds holding Fs Global Cr Opportunitie Fda

Commonwealth Equity Services
Nomura Holdings
Cambridge Investment Research Advisors
Thomas J. Herzfeld Advisors
Saba Capital Management
Wagner Wealth Management
Penserra Capital Management
Advisor Group Holdings
H D Vest Advisory Services
Rockefeller Capital Management
Royal Bank of Canada
Kestra Advisory Services
Ellis Investment Partners
Prime Capital Investment Advisors
Feltz Wealth PLAN

View all funds holding Fs Global Cr Opportunitie Fda